NASDAQ:ARQT Arcutis Biotherapeutics (ARQT) Stock Price, News & Analysis $26.19 +0.36 (+1.39%) Closing price 08/14/2026 04:00 PM EasternExtended Trading$25.83 -0.36 (-1.38%) As of 08/14/2026 07:59 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Massive. Learn more. Add Compare Share Share Stock Analysis Stock AnalysisAnalyst ForecastsChartCompetitorsEarningsFDA EventsFinancialsHeadlinesInsider TradesOptions ChainOwnershipSEC FilingsShort InterestTrendsBuy This Stock About Arcutis Biotherapeutics Stock (NASDAQ:ARQT) View Price History Chart DataSkip Price History Chart 1 Day 5 Days 30 Days 90 Days 1 Year Advanced 1 Day 1 Day 5 Days 30 Days 90 Days 1 Year Advanced Show volume Show extended hours Get ARQT alerts:Sign Up Key Stats Today's Range$25.28▼$26.2450-Day Range$21.54▼$28.7852-Week Range$15.10▼$31.77Volume1.11 million shsAverage Volume1.51 million shsMarket Capitalization$3.29 billionP/E Ratio124.72Dividend YieldN/APrice Target$35.57Consensus RatingModerate Buy Company Overview Arcutis Biotherapeutics is a clinical-stage biopharmaceutical company focused on developing and commercializing innovative therapies for immuno-inflammatory skin diseases. The company’s research and development efforts center on targeted treatments that address the underlying biology of conditions such as plaque psoriasis, atopic dermatitis, seborrheic dermatitis and vitiligo. Arcutis employs a precision-medicine approach to deliver topical therapies designed to improve efficacy and tolerability compared with existing treatment options. In August 2022, Arcutis received U.S. Food and Drug Administration approval for ZORYVE™ (roflumilast) cream, the company’s first commercial product, indicated for the treatment of plaque psoriasis in adults. Arcutis is also advancing a pipeline of next-generation roflumilast formulations, including topical ointments and foams, for the treatment of atopic dermatitis and seborrheic dermatitis. Additional clinical-stage programs include selective kinase inhibitors and other small-molecule assets aimed at expanding the company’s portfolio of dermatology therapies. Founded in 2017 and headquartered in Westlake Village, California, Arcutis has built a U.S. specialty commercial infrastructure to support the launch and market adoption of its products. The company is led by President and Chief Executive Officer Steven L. Gothel, whose leadership team brings extensive experience in dermatology drug development, regulatory affairs and commercial operations. Arcutis continues to collaborate with academic investigators and patient advocacy groups to advance its clinical programs and address unmet needs in dermatology.AI Generated. May Contain Errors. Read More Arcutis Biotherapeutics Stock Analysis - MarketRank™See Top-Rated MarketRank™ Stocks85th Percentile Overall ScoreARQT MarketRank™: Arcutis Biotherapeutics scored higher than 85% of companies evaluated by MarketBeat, and ranked 113th out of 912 stocks in the healthcare sector. Scores are calculated by averaging available category scores, with extra weight given to analysis and valuation. Analyst's Opinion4.1 / 5Analyst RatingModerate Buy Consensus RatingArcutis Biotherapeutics has received a consensus rating of Moderate Buy. The company's average rating score is 2.67, and is based on no strong buy ratings, 6 buy ratings, 3 hold ratings, and no sell ratings.Upside PotentialArcutis Biotherapeutics has a consensus price target of $35.57, representing about 35.8% upside from its current price of $26.19.Amount of Analyst CoverageArcutis Biotherapeutics has only been the subject of 4 research reports in the past 90 days.Read more about Arcutis Biotherapeutics' stock forecast and price target. Earnings and Valuation2.5 / 5Proj. Earnings Growth185.00% Earnings GrowthEarnings for Arcutis Biotherapeutics are expected to grow by 185.00% in the coming year, from $0.40 to $1.14 per share.Price to Earnings Ratio vs. the MarketThe P/E ratio of Arcutis Biotherapeutics is 124.72, which means that it is trading at a more expensive P/E ratio than the market average P/E ratio of about 45.63.Price to Earnings Ratio vs. SectorThe P/E ratio of Arcutis Biotherapeutics is 124.72, which means that it is trading at a less expensive P/E ratio than the Healthcare sector average P/E ratio of about 271.26.Price to Book Value per Share RatioArcutis Biotherapeutics has a P/B Ratio of 14.97. P/B Ratios above 3 indicate that a company could be overvalued with respect to its assets and liabilities.Read more about Arcutis Biotherapeutics' valuation and earnings. Short Interest2.0 / 5Short Interest LevelBearish Percentage of Shares Shorted11.14% of the float of Arcutis Biotherapeutics has been sold short.Short Interest Ratio / Days to CoverArcutis Biotherapeutics has a short interest ratio ("days to cover") of 10.74, which indicates bearish sentiment.Change versus previous monthShort interest in Arcutis Biotherapeutics has recently decreased by 6.45%, indicating that investor sentiment is improving significantly. Dividend0.0 / 5Dividend StrengthN/A Dividend YieldArcutis Biotherapeutics does not currently pay a dividend.Dividend GrowthArcutis Biotherapeutics does not have a long track record of dividend growth. News and Social Media3.6 / 5News Sentiment0.75 News SentimentArcutis Biotherapeutics has a news sentiment score of 0.75. This score is calculated as an average of sentiment of articles about the company over the last seven days and ranges from 2 (good news) to -2 (bad news). This is a higher news sentiment than the 0.65 average news sentiment score of Healthcare companies.News Coverage This WeekMarketBeat has tracked 11 news articles for Arcutis Biotherapeutics this week, compared to 7 articles on an average week.Search InterestOnly 3 people have searched for ARQT on MarketBeat in the last 30 days. This is a decrease of -73% compared to the previous 30 days.MarketBeat Follows4 people have added Arcutis Biotherapeutics to their MarketBeat watchlist in the last 30 days. This is an increase of 100% compared to the previous 30 days. Company Ownership1.1 / 5Insider TradingSelling Shares Insider Buying vs. Insider SellingIn the past three months, Arcutis Biotherapeutics insiders have sold more of their company's stock than they have bought. Specifically, they have bought $0.00 in company stock and sold $803,066.00 in company stock.Percentage Held by Insiders9.40% of the stock of Arcutis Biotherapeutics is held by insiders.Percentage Held by InstitutionsArcutis Biotherapeutics has minimal institutional ownership at this time.Read more about Arcutis Biotherapeutics' insider trading history. Receive ARQT Stock News and Ratings via Email Sign-up to receive the latest news and ratings for Arcutis Biotherapeutics and its competitors with MarketBeat's FREE daily newsletter. Submit View SMS TermsSMS is currently available in Australia, Belgium, Canada, France, Germany, Ireland, Italy, New Zealand, the Netherlands, Singapore, South Africa, Spain, Switzerland, the United Kingdom, and the United States. By entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy. ARQT Stock News HeadlinesArcutis Biotherapeutics (NASDAQ:ARQT) Insider Sells 6,700 Shares of StockAugust 14 at 7:36 AM | insidertrades.comArcutis (ARQT) Q2 2026 Earnings Call TranscriptAugust 13 at 9:01 AM | finance.yahoo.comThey didn't warn anyone in 1971. This time someone is warning you.On August 15, 1971, Nixon interrupted prime-time television and ended the gold standard in 15 minutes - no debate, no vote, one executive order. Gold tripled within three years and climbed 20x over the following decade. Trump holds that same executive authority today, and his advisors are openly saying a reversal is on the table. There are two ways this plays out - both move gold in the same direction. A free briefing breaks down exactly what Nixon did, why Trump is positioned to act, and how to move your 401k into gold before any announcement - tax free.August 16 at 1:00 AM | Reagan Gold Group (Ad)HC Wainwright Has Positive Forecast for ARQT Q3 EarningsAugust 10, 2026 | americanbankingnews.comArcutis Biotherapeutics (NASDAQ:ARQT) Price Target Raised to $40.00August 9, 2026 | americanbankingnews.comWhat is HC Wainwright's Estimate for ARQT Q1 Earnings?August 9, 2026 | americanbankingnews.comArcutis Biotherapeutics (NASDAQ:ARQT) Raised to Strong-Buy at Wall Street ZenAugust 8, 2026 | americanbankingnews.comArcutis Biotherapeutics (NASDAQ:ARQT) Insider Sells $24,944.60 in StockAugust 6, 2026 | insidertrades.comSee More Headlines ARQT Stock Analysis - Frequently Asked Questions How have ARQT shares performed this year? Arcutis Biotherapeutics' stock was trading at $29.04 on January 1st, 2026. Since then, ARQT shares have decreased by 9.8% and is now trading at $26.19. How were Arcutis Biotherapeutics' earnings last quarter? Arcutis Biotherapeutics, Inc. (NASDAQ:ARQT) released its earnings results on Wednesday, August, 5th. The company reported $0.11 earnings per share for the quarter, topping analysts' consensus estimates of $0.06 by $0.05. The business earned $129.86 million during the quarter, compared to analysts' expectations of $118.85 million. Arcutis Biotherapeutics had a trailing twelve-month return on equity of 15.05% and a net margin of 6.15%. Read the conference call transcript. When did Arcutis Biotherapeutics IPO? Arcutis Biotherapeutics (ARQT) raised $150 million in an initial public offering on Friday, January 31st 2020. The company issued 9,375,000 shares at a price of $15.00-$17.00 per share. Goldman Sachs, Cowen and Guggenheim Securities served as the underwriters for the IPO and Cantor was co-manager. Who are Arcutis Biotherapeutics' major shareholders? Arcutis Biotherapeutics' top institutional investors include BlackRock Inc. (8.43%), Jupiter Topco LLC (1.12%), The Manufacturers Life Insurance Company (0.65%) and Deutsche Bank AG (0.31%). Insiders that own company stock include Life Sciences Viii L Frazier, Todd Franklin Watanabe, Todd Watanabe, Larry Todd Edwards, David Joseph Topper, Masaru Matsuda, Patrick Burnett, Latha Vairavan, Howard G Welgus, Sue-Jean Lin, Patrick J Heron, Neha Krishnamohan, Halley E Gilbert and Terrie Curran. View institutional ownership trends. How do I buy shares of Arcutis Biotherapeutics? Shares of ARQT stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services. What other stocks do shareholders of Arcutis Biotherapeutics own? Based on aggregate information from My MarketBeat watchlists, some other companies that Arcutis Biotherapeutics investors own include Invesco QQQ (QQQ), NVIDIA (NVDA), Advanced Micro Devices (AMD), SPDR S&P 500 ETF Trust (SPY), Tesla (TSLA), Meta Platforms (META) and SPDR Dow Jones Industrial Average ETF Trust (DIA). Company Calendar Last Earnings8/05/2026Today8/16/2026Next Earnings (Estimated)10/27/2026Fiscal Year End12/31/2026Get Stock Alerts Health Indicator TradeSmith's Health IndicatorA long-term volatility-based measure designed for securities held 12 months or longer.Green: Strong and healthy uptrend with normal pullbacks.Yellow: Significant pullback but still within expected volatility.Red: Dropped beyond expected volatility; considered unhealthy. Green Zone (24m+) 1-Year History Aug 25 Nov 25 Feb 26 May 26 Aug 26 ARQT's financial health is in the Green zone, according to TradeSmith. ARQT has been in this zone for over 24 months. Industry, Sector and Symbol Stock ExchangeNASDAQ SectorHealthcare Industry Pharmaceuticals Sub-IndustryPharmaceuticals Current SymbolNASDAQ:ARQT CIK1787306 Webwww.arcutis.com Phone805-418-5006FaxN/AEmployees150Year Founded2016Price Target and Rating Average Price Target for Arcutis Biotherapeutics$35.57 High Price Target$40.00 Low Price Target$29.00 Potential Upside/Downside+35.8%Consensus RatingModerate Buy Rating Score (0-4)2.67 Research Coverage9 Analysts Profitability EPS (Trailing Twelve Months)$0.21 Trailing P/E Ratio124.72 Forward P/E Ratio65.48 P/E GrowthN/ANet Income-$16.14 million Net Margins6.15% Pretax Margin6.31% Return on Equity15.05% Return on Assets6.51% Debt Debt-to-Equity Ratio0.46 Current Ratio2.92 Quick Ratio2.67 Sales & Book Value Annual Sales$376.07 million Price / Sales8.75 Cash FlowN/A Price / Cash FlowN/A Book Value$1.75 per share Price / Book14.97Miscellaneous Outstanding Shares125,690,000Free Float113,877,000Market Cap$3.29 billion OptionableOptionable Beta1.49 Social Links The Infrastructure's Backbone: 10 Stocks Powering the AI BuildoutThe AI boom extends far beyond the biggest tech names. Discover 10 companies supplying the memory, storage, networking, semiconductor manufacturing, and power infrastructure that make AI possible. Learn where the next wave of AI investment opportunities may emerge—and the key risks investors should watch as the global AI buildout accelerates.Get This Free Report This page (NASDAQ:ARQT) was last updated on 8/16/2026 by MarketBeat.com Staff. From Our PartnersMan who Predicted Trump 2016 Win: “Prepare for Mid-Term Meltdown”In 2016, major election models gave Hillary Clinton a 99% chance of winning - but former CIA and Pentagon advi...Paradigm Press | SponsoredHere’s the stock symbol I’ve promisedWhitney Tilson of Stansberry Research has long recommended Berkshire Hathaway as a core retirement holding - b...Stansberry Research | SponsoredBuy These Stocks Before August 31stKeith Kaplan has invested $17 million into his own AI research platform, now used by 180,000 investors worldwi...TradeSmith | SponsoredThis tiny launch company operates next to SpaceX and Blue OriginA small publicly traded company operates a specialized launch vehicle fleet inside the secure perimeter of Ken...Freedom Financial | SponsoredALERT: Drop these 5 stocks before the market opens tomorrow!The Wall Street Journal is already raising the alarm about a potential market crash, and Weiss Ratings researc...Weiss Ratings | SponsoredThese gold assets are priced for $1,800 gold [it's over $4,000]Gold's major miners are generating record free cash flow, with margins as high as 75 percent even after gold's...Golden Portfolio | SponsoredMy top 3 AI picks for the next decadeAlexander Green bought Apple in 1996, recommended Nvidia at a split-adjusted 66 cents in 2004, and picked up A...The Oxford Club | SponsoredRay Dalio: Buy Gold. Get Paid.Ray Dalio, founder of Bridgewater Associates, is urging investors to hold 15% of their portfolio in gold and c...Investors Alley | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added ten stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Arcutis Biotherapeutics, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share Arcutis Biotherapeutics With A Colleague Link copied to clipboard. Unlock superior investment research and tools. Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools and reports. Get MarketBeat All Access MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In Email Me a Login Link or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
